SolarRevolution
2 weeks ago
News!!
Vancouver, British Columbia--(Newsfile Corp. - August 21, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it has been issued three U.S. patents: one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation.
The method of use patent, entitled "Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders" relates to INM-755 drug candidate which has completed a Phase 2 clinical trial in the treatment of symptoms related to epidermolysis bullosa. The patent has now been granted in the U.S., Australia, Japan and Israel and is pending in several other jurisdictions. The biosynthesis patent for the manufacturing of proprietary analogs for our drug development programs has been granted in U.S. Additionally, an ocular drug delivery formulation and use patent has been granted/allowed in the U.S., Europe, Australia, Japan, and India and is also pending in other jurisdictions.
As of August 20, 2024, InMed has a total of 13 patent families covering new chemical entities, formulations, manufacturing processes and methods of use. The Company continues to pursue new chemical entity patents on the drug candidates for both its INM-901 program in Alzheimer's disease and INM-089 in dry Age-related Macular Degeneration.
Summary of Granted Patents (to date):
Subject Matter
Scope
Status and jurisdiction
Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
Method of Use
Granted: US, Australia, Japan, Israel
Pending: Several jurisdictions
Metabolic engineering of E. coli for the biosynthesis of cannabinoid products
Manufacturing Process
Granted: U.S. (will be issued on 9/3/24)
Pending: Several jurisdictions
Ocular drug delivery formulation
Formulation, Method of Use
Granted/Allowed: Australia, Japan, India, Europe, U.S.
Recombinant production systems for prenylated polyketides of the cannabinoid family
Manufacturing Process
Granted: U.S., Mexico
Pending: Several jurisdictions
InMed's President and CEO, Eric A. Adams, said "We are pleased to announce these U.S. patent issuances which help increase the commercial value of our programs and ensure the long-term protection of our drug research and development efforts. We are committed to continuing to build our patent portfolio to protect our novel drug candidates, methods of manufacturing these drugs, how they are formulated and how they are used to support the development of new treatments for diseases with high unmet medical needs."